

26 August 2026

Biological Treatments for Atopic Dermatitis

1. How many patients were treated in the last 4 months (April to July 2026) by the dermatology department with each of the following products:

• Abrocitinib	10
• Acitretin	0
• Alitretinoin	0
• Azathioprine	0
• Baricitinib	<5
• Ciclosporin	0
• Dupilumab	298
• Lebrikizumab	18
• Methotrexate	0
• Mycophenolate mofetil	0
• Pimecrolimus	0
• Phototherapy (UVB or PUVA) - for Atopic Dermatitis only	0
• Tacrolimus ointment	0
• Tralokinumab	0
• Upadacitinib	44
• Nemolizumab	15

2. In the last 4 months, how many new patients have been initiated* on the following treatments by the dermatology department:

• Abrocitinib	<5
• Baricitinib	0
• Dupilumab	38
• Lebrikizumab	8
• Tralokinumab	0
• Upadacitinib	<5
• Nemolizumab	12

*Patients are considered initiated if they have not been treated in the previous 8 months with any of the drugs that are part of the named regimen

26 August 2026

3. Of the patients treated in the last 4 months with any of the products listed in question 1, please provide the number of patients by the following age group:

- | | |
|--------------------|-----|
| • 6 months to 5 | 6 |
| • Age 6-11 | 19 |
| • Age 12-17 | 36 |
| • Age 18 and above | 326 |

4. How many patients have received treatment by the dermatology department for Prurigo Nodularis in the last 4 months with each of the following products:

- | | |
|---------------|----|
| • Dupilumab | 5 |
| • Nemolizumab | <5 |

Some figures have been withheld and replaced with less than five (<5), this is due to the small geographical area of NI and releasing the actual figure has the potential to make the patient identifiable.